This site is part of the Siconnects Division of Sciinov Group

This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.

ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR

Registration
logo_not_found
Event
Hybrid Event

Accelerate Ideas, Partnerships and Opportunities

Book your SLOT NOW
  • Start 9:00am - 6:00pm
  • Rome, Italy
    Registration Venue
     

    About Conference

    Sciinov Group is proud to announce the Oligonucleotide Therapeutics and Delivery Conference on September 15-16, 2025, in Rome, Italy. This year's OTDC 2025 annual Oligonucleotide Therapeutics and Delivery conference will showcase recent advances in oligonucleotide development, regulatory requirements and CMC considerations, strategies to enhance oligonucleotide discovery, and targeting and optimizing delivery techniques for oligonucleotide-based therapies in the hope of continuing to drive forward the field of Readmore

    Author's Login
    Abstract Tracking Tool

    Scientific Sessions

    ask & questions

    answer

    We are always looking for new industry leaders to join our speaker faculty to deliver presentations, lead panel discussions and moderate sessions or roundtables. 
    If you are interested in being considered as a speaker, submit your proposal/abstract Online

    answer

    We let speakers propose the topic they want to talk about. This process allows speakers to propose sessions that speak from their expertise and passion.
    Speaker can choose the topic of your choice in related to the conference subject or any of their recent research work to present at our conference.
    For details of scientific sessions covered please visit [not limited to, you can propose]  

     

    answer

    Please visit the page here

    answer

    Yes, as our conference is scheduled in Hybrid Mode, you can present and listen to full program virtually connecting via ZOOM live stream


    view all Faq's

    Recent Updates

    Feb 22
    2022

    Ansa Biotechnologies Achieves Breakthrough in DNA Synthesis

    Ansa Biotechnologies is also launching an Early Access Program aimed at helping researchers obtain synthetic genes with sequences that were previously challenging to synthesizeReadmore

    21 Aug
    2023

    Qalsody is an antisense oligonucleotide that targets SOD1 mRNA

    FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosisReadmore

    9 MAR
    2023

    Ansa Biotechnologies Announces Successful de novo Synthesis of World’s Longest Oligonucleotide at 1005 Bases

    Ansa will be initiating an Early Access Program for clonal synthetic genes in April 2023Readmore

    Feb 22
    2022

    Secarna Pharmaceuticals’ partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration

    Secarna’s LNAplusTM antisense oligonucleotides (ASOs) combined with Denali’s Oligonucleotide Transport Vehicle (OTV) technology provide potential for novel therapies in the area of difficult-to-treat central nervous system (CNS) diseasesReadmore


    view all Updates
    08:00-09:00

    Registration

    09:00-09:30

    Opening Ceremony and Introduction

    09:30-10:10

    Keynote Session I

    10:10-10:50

    Keynote Session II

    10:50-11:00

    Refreshment Break

    11:00-15:00

    Break Out Session I

    15:00-15:10

    Refreshment Break

    15:10-18:00

    Break Out Session II

    09:30-10:10

    Keynote Session III

    10:10-10:50

    Keynote Session IV

    10:50-11:00

    Refreshment Break

    11:00-15:00

    Break Out Session III

    15:00-15:10

    Refreshment Break

    15:10-18:00

    Break Out Session IV

    Get more information

    make a booking now

    Market Reports

    view all Reports

    Subscribe to our News & Updates